PF-07104091 as a Single Agent and in Combination Therapy
Small Cell Lung Cancer · Ovarian Cancer · Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 157 (final count)
- Started
- Sep 16, 2020
- Main results expected
- Dec 31, 2026
- Fully finished
- Dec 31, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycle
Measured over: 28 days
To evaluate incidence of treatment emergent adverse events and laboratory abnormalities
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
Evaluate pulse rate that is out of normal range and changes in pulse rate as compared to baseline
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
Evaluate blood pressure that is out of normal range and changes in blood pressure as compared to baseline
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
To evaluate heart rate corrected QT interval and changes in corrected QT interval as compared to baseline
Measured over: From baseline until end of study treatment or study completion (approximately 2 years)
To evaluate the preliminary antitumor activity of PF-07104091 as a single agent and in combination with palbociclib and in combination with letrozole or fulvestrant or fulvestrant alone by objective response rate (ORR) in dose expansion
Measured over: From baseline through disease progression or study completion (approximately 2 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04553133 · record last updated 2026-05-06 · checked 2026-11-09 15:36 UTC